INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 149 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q1 2018. The put-call ratio across all filers is 0.95 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $358,218 | +131.1% | 26,673 | +137.8% | 0.12% | +51.9% |
| Q2 2022 | $155,000 | -52.5% | 11,216 | +173.6% | 0.08% | -64.5% |
| Q2 2019 | $326,000 | -71.8% | 4,099 | -79.3% | 0.22% | -35.8% |
| Q4 2017 | $1,156,000 | +123.6% | 19,786 | +122.3% | 0.34% | +131.5% |
| Q3 2017 | $517,000 | -28.8% | 8,900 | +48.3% | 0.15% | -41.8% |
| Q2 2017 | $726,000 | +64.6% | 6,000 | +53.8% | 0.25% | +39.4% |
| Q1 2017 | $441,000 | – | 3,900 | – | 0.18% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Carmignac Gestion | 2,028,192 | $229,389,000 | 1.76% |
| Orbimed Advisors | 1,037,000 | $117,285,000 | 1.33% |
| BB BIOTECH AG | 255,719 | $28,922,000 | 0.95% |
| ALTRINSIC GLOBAL ADVISORS LLC | 193,369 | $21,870,000 | 0.74% |
| FALCON POINT CAPITAL, LLC | 44,573 | $5,041,000 | 0.67% |
| Rhenman & Partners Asset Management AB | 30,000 | $3,393,000 | 0.54% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 11,155 | $1,262,000 | 0.48% |
| NATIONAL PLANNING CORP | 52,400 | $5,888,000 | 0.44% |
| HIGHFIELDS CAPITAL MANAGEMENT LP | 364,232 | $41,195,000 | 0.38% |
| SPHERA FUNDS MANAGEMENT LTD. | 15,000 | $1,697,000 | 0.33% |